Managing neoplastic bone disease with ibandronic acid: A preclinical and clinical data update

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3111-3119

  Pecherstorfer, Martin ^a  

^a Hematologic Oncologic Service   (Austria)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Efficacy; Ibandronic acid; Intravenous; Oral; Safety

Indexed keywords

CAPECITABINE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EPIRUBICIN; IBANDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; TAXOID; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE CANCER; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EROSION; ESOPHAGITIS; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; JAW OSTEONECROSIS; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; NAUSEA; OSTEOLYSIS; QUALITY OF LIFE; REVIEW; STOMACH IRRITATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; DRUG TOLERANCE; HUMANS; PAIN;

EID: 57549098965     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802482945     Document Type: Review

References (83)

1. Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 2006;11(suppl 1):27-33
2. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-95
3. Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 2005;5(suppl 2):S54-62
4. Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control 2002;9:480-9
5. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-24
6. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
7. Finley RS. Bisphosphonates in the treatment of bone metastases. Semin Oncol 2002;29(suppl 4):132-8
8. Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother 2004;5:2341-50
9. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
10. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367-401
11. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:s6222-30
12. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(suppl 2):S150-62
13. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on how mechanisms of action relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57
14. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(suppl 12):2961-78
15. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11
16. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-76
17. Ralston SH, Thiébaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300
18. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
19. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405
20. Body JJ, Diel IJ, Lichinitser MR, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br J Cancer 2004a;90:1133-7
21. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. The Oncologist 2005;10(suppl 1):8-13
22. Heras P, Karagiannis S, Kritikos K, et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 2007;16:539-42
23. Mystakidou K, Stathopoulou E, Parpa E, et al. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. Cancer Res Clin Oncol 2008 May 27
24. Clemons M, Cole DE, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer Breast Cancer Res Treat 2006;97:81-90
25. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69
26. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35
27. Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007;18:1165-71
28. Paterson AHG. The role of bisphosphonates in early breast cancer. Oncologist 2006;11(suppl 1):13-9
29. Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial. Bone 2006;38(suppl 1):S82
30. Vassiliou V, Kalogeropoulou C, Christopoulos C, et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007;67(1):264-72
31. Bell R, Diel IJ, Body JJ, Bergström B. Renal safety of ibandronate in patients with bone metastases from breast cancer: Phase III trial results. Eur J Cancer Suppl 2004;2:132
32. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-12
33. Diel IJ, Body JJ, Bergström B. Low nephrotoxicity of ibandronate: implications for the management of patients with metastatic bone disease. Support Care Cancer 2004;12:406-7
34. Clemons M, Dranitsaris G, Ooi W, et al. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2008;108:79-85
35. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-92
36. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-5
37. Heidenreich A, Ohlmann C, Olbert P, et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S270
38. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54
39. Hiraga T, Williams PJ, Mundy GR, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24
40. Neudert M, Fischer C, Krempien B, et al. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003;107:468-77
41. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44
42. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 2000;15:2211-21
43. Magnetto S, Boissier S, Delmas PD, Clézardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9
44. Journe F, Chaboteaux C, Magne N, et al. Additive growth inhibitory effects of ibandronate and antioestrogens in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2006;8:R2
45. Cartenì G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006;11:841-8
46. Gordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, Phase III trials. Clin Breast Cancer 2005;6:125-31
47. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907
48. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-12
49. Bergström B, Lichinitser M, Body JJ. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative Phase II/III trials. Bone 2006;38(suppl 1):S68
50. Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133-52
51. Aapro M, Abrahansson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals Oncol 2008;19:1407-16
52. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer - results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99:765-76
53. Suri S, Mönkkönen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001;29:336-43
54. Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 1996;53:1917-27
55. von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 2005;10(suppl 1):19-24
56. McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:43-8
57. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-7
58. Oh WK, Proctor K, Nakabayashi M, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;109:1090-6
59. Bergner R, Diel IJ, Henrich D, et al. Differences in the nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-40
60. De Lemos ML, Taylor SC, Barnett JB, et al. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database. J Oncol Pharm Pract 2006;12:193-9
61. Body JJ, Diel IJ, Tripathy D, Bergström B: Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results. Eur J Cancer Care (Engl) 2006;15:299-302
62. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315-22
63. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicol 2003;191:159-67
64. Pfister T. Comparative renal effects of two intravenously administered bisphosphonates. Toxicol 2004;196:169-70
65. Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 2006;26:3133-6
66. von Moos R, Thürlimann B, Caspar CB, et al. Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: a randomized, open-label study. J Clin Oncol 2007;25(18S):1114
67. Body JJ, Coleman R, Clezardin P, et al. International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007b;43:852-8
68. Body JJ. Safety and tolerability of bisphosphonates in the elderly: objective data. Presented at the 6th Meeting of ISGO/SIOG, Geneva; 2005
69. Henrich D, Hoffman M, Uppenkamp M, et al. Ibandronate for the treatment of hypercalcemia or nephrocalcemia in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 2006;116:165-72
70. Bergner R, Henrich DM, Hoffman M. Renal safety and pharmacokinetics of ibandronic acid in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007;47:942-50
71. Krueger CD, West PM, Sargent M, et al. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 2007;41:276-84
72. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3
73. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006;12:s6258-63
74. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7
75. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60
76. Guarneri V, Donati S, Nicolini M, et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005;10:842-8
77. Tassinari D, Poggi B, Nicoletti S, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 2007;10:352-8
78. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leuk 2007;21:1545-8
79. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71
80. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14
81. Mystakidou K, Katsouda E, Stathopoulou E, et al. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 2005;31:303-11
82. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005;27:1295-310
83. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005;13:975-86